A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

  • Interventional
  • Not Recruiting
  • NCT02261220
Eligibility Details Visit Clinicaltrials.gov

A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors

This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.

Gender
All

Age Group
18 Years to 99 Years

Accepting Healthy Volunteers?
No

Inclusion Criteria:

         - Male and female subjects

         - 18 years and older

         - Histologic confirmation of advanced solid tumors

         - Subjects must have recurrent/metastatic disease and may have been previously treated in the recurrent/metastatic setting.

        Exclusion Criteria:

         - Any concurrent chemotherapy, immune-mediated therapy or biologic or hormonal therapy for cancer treatment

         - Active or prior documented autoimmune disease within the past 2 years

         - Current or prior use of immunosuppressive medication within 14 days with some exceptions.
  • Solid Tumors

At a Glance

National Government IDNCT02261220

IRB#IRB14-1429

Lead SponsorMedImmune LLC

Lead PhysicianDaniel Catenacci

Collaborator(s)N/A

EligibilityAll
18 Years to 99 Years
Not Recruiting